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Adolescents in South Africa are at high risk of HIV infection. In
2002 it was estimated that 9.3% of youth (15 - 24 years) were
HIV infected.1 Another survey in 20032 reported that 10.2% of
this same age group were infected. In the 15 - 19-year age
group, 4.8% of youths were reportedly infected with HIV.2 The
participation of children in research, including HIV vaccine
trials, ensures their fair access to safe and efficacious products.
Adolescents are, however, a vulnerable group and their
participation raises complex ethical and legal issues.
South African ethical-legal framework 
The ethical-legal framework governing child research in South
Africa is currently in transition. Firstly, a comprehensive new
legislative framework for health research is being implemented
through the National Health Act.3 Secondly, the legislation
relating to children is being reviewed and consolidated into a
Children’s Bill.4 Thirdly, a number of new ethical guidelines
have been published and a series of others are being revised.
Fourthly, the institutional framework for establishing research
priorities and regulation of ethical review is being strengthened
with the establishment of new institutions such as the National
Health Research Ethics Committee.  
The South African ethical-legal framework and its
implications for adolescent HIV vaccine trials were debated at
a forum convened by the HIV AIDS Vaccine Ethics Group
(HAVEG), funded by the South African AIDS Vaccine Initiative
(SAAVI). Representatives from a variety of stakeholder groups
including research ethics committees (RECs) and community
advisory boards were invited to the forum that aimed to: (i)
identify the complexities posed by the current ethical-legal
framework and implications for HIV vaccine trials, with a
focus on child participation (including adolescents); and (ii)
work towards consensus on how to enhance the current
framework so that it would facilitate sound research and
protect trial participants.
The major themes and recommendations of the forum are
presented here.
Key outcomes
The South African ethical-legal framework is in a
state of flux due to legislative and ethical guideline
changes
Key problems raised at the forum included: (i) although the
National Health Act3 has been passed by parliament not all
aspects of the Act have been implemented; (ii) the regulations
that accompany the Act3 and that contain much of the detail
regarding its practical application have yet to be finalised; (iii)
the Children’s Bill,4 which proposes considerable amendments
to the health rights of children, has not yet been passed by
parliament; and (iv) it is uncertain when the revision of key
ethical guidelines will be finalised.5,6
As a result investigators, RECs and other stakeholders face
an uncertain ethical-legal environment. For example, Section
71(2) of the National Health Act3 requires consent from both
the parent/guardian and the child, regardless of age, for all
research including ‘therapeutic’ research. Unlike existing and
proposed children’s legislation, the Act does not provide for a
child of a specified age or capacity to give independent
consent. For example, section 39 of the Child Care Act (Act No.
74 of 1983) allows a child of 14 years to consent independently
to ‘medical treatment’, which legal scholars and RECs have
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The ethical-legal framework in South Africa is in a period of
transition, with a number of new developments changing the
substantive principles and procedures for health research in the
country. Some of the changing dynamics include both law
reform and the review of ethical guidelines. This changing
environment poses many complexities for researchers, research
ethics committees and participating communities involved in
planning, implementing and reviewing research with child
participants, including HIV vaccine trials. This paper presents
the major themes and outcomes of a consultative meeting
convened by the HIV AIDS Vaccines Ethics Group in July 2004
for key stakeholder groups. At this forum participants
discussed the complexities posed by a transitional and
sometimes contradictory ethical-legal framework and how the
framework could be improved to simultaneously promote
critical research and the welfare of child participants.
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interpreted as allowing children over 14 to consent
independently to ‘therapeutic’ research.7
Researchers will now face new legal requirements that may
affect recruitment and informed consent processes. Although
the National Health Act3 will not operate retrospectively, once
it is implemented researchers may have to change current
practices if they are not in line with the new provisions. 
Aspects of the emerging ethical-legal framework are
ambiguous and inconsistent
Key problems raised at the forum included:
1. The National Health Act3 retains the contested distinction
between ‘therapeutic’ and ‘non-therapeutic’ research in its
provisions relating to research with children, despite the fact
that most research contains interventions not intended to
confer direct benefit to participants. It does not define either
term.
2. It is not clear how the different phases of HIV vaccine trials
would be classified in terms of the above distinction.
3. If HIV vaccine trials are classified as ‘non-therapeutic’
research (as early trials might be) the risk standard of ‘not
significant’ risk must be met. There was some debate as to
whether the above term introduced a more relaxed standard
of risk for research involving children or alternatively
whether it was substantively identical to current risk
standards (routine tests or daily life). There was some debate
as to whether the risks of HIV vaccine research (such as
vaccine administration, risk assessments) could meet this
standard set by the National Health Act.3
4. There are many inconsistencies between the National Health
Act3 and other critical pieces of legislation such as the
Children’s Bill.4 For example, the National Health Act3
requires dual consent for research from parents or legal
guardians and where children are capable of understanding,
children themselves.8 This differs from the approach taken in
the Children’s Bill4 which provides for independent consent
by a child of a specified age and capacity (albeit in the case
of medical treatment and operations and not research),
which creates a wider category of persons who are able to
act on a child's behalf,9 and which requires that the views of
a child be given due consideration bearing in mind the age,
maturity and stage of development of the child.10
5. The National Health Act3 requires ‘therapeutic’ research to be
conducted only if it is in the ‘best interests’ of the child.11 No
guidance is provided in the Act on how one establishes what
these ‘best interests’ are. 
6. Both the National Health Act3 and the Children’s Bill4
provide that in the event of an inconsistency their provisions
will prevail.
7. Four ethical guidelines relevant to HIV vaccine research5,6,12,13
offer some contradictory guidance regarding child
participation on the following points: (i) the approach taken
towards the analysis of risk and classification of research; (ii)
the name given to risk levels allowed for child research, and
the substance of the risk level allowed for child research; (iii)
who has the authority to consent for child participation; and
(iv) what risk parents or guardians are permitted to consent
to on behalf of children when there is no direct benefit to the
child and when there is a direct benefit.
It is the MRC’s General Principles6  that are most disjunctive
with the other three increasingly well-harmonised guide-
lines.5,12,13  As a result of these ambiguities and inconsistencies
REC members reviewing trials and researchers planning trials
may struggle to screen out ‘unethical’ or unlawful research
practices involving child participants.
In some instances, the ethical-legal framework does
not protect child welfare or promote critical research
as effectively as possible
The following issues were discussed:
1. Section 71 of the National Health Act3 purports to deal with
the rights of children participating in research; however, it
focuses on informed consent without considering other
protections such as a child’s right to privacy. As a result,
there are many instances in which child research participants
do not have explicit legal protection in South African law.
2. The National Health Act3 creates additional procedural
requirements that may burden investigators and RECs, e.g.
when ‘non-therapeutic’ research is conducted on children
then ‘authorisation from the Minister’ must be obtained.14
Furthermore, the Minister is obliged to follow guidelines set
down in the Act, in determining whether authorisation for
non-therapeutic research should be approved. Concerns
were raised regarding: (i) how this provision would operate
in practice; (ii) whether it would delay research classified as
‘non-therapeutic’; and (iii) how the Minister would interpret
poorly drafted requirements such as that research may only
be authorised if the parent or minor’s reasons for consenting
to the research are not contrary to public policy.
3. Certain ethical guidelines are restrictive in their approach,
e.g. the Medical Research Council’s General Principles6
permit parents to enroll their children in ‘non-therapeutic’
research only if it is ‘observation’ research, and research with
risks not exceeding everyday life. This approach may
prevent the enrolment of healthy children in intervention
research such as clinical trials of prevention products.
Recommendations
A number of recommendations were made at the forum to
promote a more coherent framework that facilitates critical
research with child participants, including adolescents, while
promoting their rights and welfare.  These included the
following.
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Capacity should be built for stakeholders to better
understand the strengths, weaknesses and
implications of the framework, and mechanisms
should be developed to allow them to impact on the
framework
It was recognised that in many instances stakeholders felt
unable to participate in the ethical-legal framework or impact
on its development because of a lack of capacity. Accordingly it
was recommended that: (i) the capacity of community
representatives, RECs and investigators should be developed
to enable them to understand the relevant laws and guidelines,
and their interpretation in relation to HIV vaccine research; (ii)
an accurate understanding of the perspectives and concerns of
participating communities should be established through
sensitive research and consultation; and (iii) mechanisms
should be developed whereby stakeholders, such as RECs, can
liaise on the interpretation of laws or guidelines in order to
aspire towards consistent protocol review.
Law reform and the revision of ethical guidelines is
required
The following was recommended: (i) input should be made to
the regulations that will accompany the National Health Act in
order to resolve certain inconsistencies and ambiguities in the
Act;3 (ii) proposals to include the rights of child research
participants in the Children’s Bill4 should be supported; and
(iii) revisions should be made to ethical guidelines5,6 that ensure
their harmonisation and ability to protect child participants
while accommodating sound research.
Appropriate tools should be developed
It was recommended that tools and tests should be developed
to facilitate the appropriate implementation of a number of the
new requirements set out in the National Health Act including:
(i) children’s ‘understanding’ of research participation; (ii)
determining ‘public policy’; and (iii) determining the ‘best
interests of the child’.
In conclusion, a transitory and inconsistent framework
complexifies research involving adolescent or child
participants. Considerable training, law reform, guideline
amendment and tool development are required to better
protect these participants and to facilitate critical research to
promote their health.
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